DK1349944T3 - Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens - Google Patents
Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latensInfo
- Publication number
- DK1349944T3 DK1349944T3 DK02729440T DK02729440T DK1349944T3 DK 1349944 T3 DK1349944 T3 DK 1349944T3 DK 02729440 T DK02729440 T DK 02729440T DK 02729440 T DK02729440 T DK 02729440T DK 1349944 T3 DK1349944 T3 DK 1349944T3
- Authority
- DK
- Denmark
- Prior art keywords
- latency
- pharmaceutically active
- fusion protein
- associated peptide
- nucleic acid
- Prior art date
Links
- 101800001155 Latency-associated peptide Proteins 0.000 title abstract 3
- 102400000401 Latency-associated peptide Human genes 0.000 title abstract 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 abstract 5
- 102000037865 fusion proteins Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000006337 proteolytic cleavage Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0100551.1A GB0100551D0 (en) | 2001-01-09 | 2001-01-09 | Protein |
| US09/756,283 US6942853B2 (en) | 2001-01-09 | 2001-01-09 | Latent fusion protein |
| PCT/GB2002/000068 WO2002055098A2 (en) | 2001-01-09 | 2002-01-09 | Latency associated peptide for providing latency to pharmaceutically active proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1349944T3 true DK1349944T3 (da) | 2005-07-25 |
Family
ID=26245544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02729440T DK1349944T3 (da) | 2001-01-09 | 2002-01-09 | Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6942853B2 (enExample) |
| EP (1) | EP1349944B1 (enExample) |
| JP (1) | JP4201253B2 (enExample) |
| AT (1) | ATE293169T1 (enExample) |
| AU (1) | AU2002219345B2 (enExample) |
| DE (1) | DE60203692T2 (enExample) |
| DK (1) | DK1349944T3 (enExample) |
| ES (1) | ES2240740T3 (enExample) |
| GB (1) | GB0100551D0 (enExample) |
| WO (1) | WO2002055098A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141392B2 (en) * | 2001-01-09 | 2006-11-28 | Queen Mary And Westfield College | Latent fusion protein |
| CA2475388A1 (en) * | 2002-02-14 | 2003-08-21 | William J. Rutter | Chimeric molecules for cleavage in a treated host |
| CA2624802A1 (en) * | 2005-10-04 | 2007-04-19 | Greenville Hospital System | Latent procytotoxins and uses thereof |
| DE102006009324A1 (de) | 2006-03-01 | 2007-09-06 | Dr.Ing.H.C. F. Porsche Ag | Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0724556D0 (en) * | 2007-12-17 | 2008-01-30 | Queen Mary & Westfield College | LAtency associated protein construct with aggrecanase sensitive cleavage site |
| FR2932190A1 (fr) * | 2008-06-10 | 2009-12-11 | Commissariat Energie Atomique | Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease |
| WO2010117848A1 (en) | 2009-03-31 | 2010-10-14 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
| GB0911365D0 (en) | 2009-06-30 | 2009-08-12 | Bioceramic Therapeutics Ltd | Multicomponent glasses for use as coatings and in personal care products |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| EP2878308B1 (en) * | 2013-12-02 | 2018-10-31 | Thomas Harder | Agents and methods for the suppression of T cell activation |
| GB201411506D0 (en) | 2014-06-27 | 2014-08-13 | Univ London Queen Mary | Modified latency associated protein construct |
| JP6516235B2 (ja) * | 2014-10-31 | 2019-05-22 | 国立大学法人富山大学 | キメラタンパク質及びそれを用いたミクログリア活性阻害剤 |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210130430A1 (en) | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CN113286812B (zh) | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| ES2780274A1 (es) * | 2019-02-15 | 2020-08-24 | Consejo Superior De Investig Científicas (Csic) | Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente |
| BR112021022666A2 (pt) | 2019-05-14 | 2022-03-29 | Werewolf Therapeutics Inc | Frações de separação e seus métodos e uso |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| GB202004679D0 (en) | 2020-03-31 | 2020-05-13 | Stealthyx Therapeutics Ltd | Modified latercy associated protein construct |
| AU2021254283B2 (en) * | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| CA2003886A1 (en) | 1988-12-16 | 1990-06-16 | Anthony F. Purchio | Cloning and expression of simian transforming growth factor-beta 1 |
| WO1991008291A2 (en) | 1989-11-22 | 1991-06-13 | Genentech, Inc. | Latency associated peptide and uses therefor |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| EP0698094B1 (en) | 1993-05-12 | 2004-02-04 | Genetics Institute, LLC | Bmp-11 compositions |
| EP0704532B1 (en) | 1994-06-10 | 2002-09-11 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
| US5800811A (en) * | 1995-06-06 | 1998-09-01 | Hall; Frederick L. | Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site |
| CA2232669A1 (en) * | 1995-09-27 | 1997-04-03 | Frances Joanne Morling | Recombinant viruses incorporating a protease cleavable protein |
| DE19701141C1 (de) | 1997-01-16 | 1998-04-09 | Hoechst Ag | Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen |
| US6593132B1 (en) * | 1997-04-30 | 2003-07-15 | Twinstrand Therapeutics Inc. | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| GB2324960A (en) | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
| JP3762222B2 (ja) | 1998-10-07 | 2006-04-05 | ストライカー・コーポレーション | 改変型ＴＧＦ−βスーパーファミリータンパク質 |
| JP2004508838A (ja) * | 2000-09-11 | 2004-03-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 組合せ蛍光エネルギー移動タグ及びそれらの使用 |
-
2001
- 2001-01-09 GB GBGB0100551.1A patent/GB0100551D0/en not_active Ceased
- 2001-01-09 US US09/756,283 patent/US6942853B2/en not_active Expired - Lifetime
-
2002
- 2002-01-09 EP EP02729440A patent/EP1349944B1/en not_active Expired - Lifetime
- 2002-01-09 JP JP2002555832A patent/JP4201253B2/ja not_active Expired - Fee Related
- 2002-01-09 ES ES02729440T patent/ES2240740T3/es not_active Expired - Lifetime
- 2002-01-09 DK DK02729440T patent/DK1349944T3/da active
- 2002-01-09 AU AU2002219345A patent/AU2002219345B2/en not_active Ceased
- 2002-01-09 WO PCT/GB2002/000068 patent/WO2002055098A2/en not_active Ceased
- 2002-01-09 DE DE60203692T patent/DE60203692T2/de not_active Expired - Lifetime
- 2002-01-09 AT AT02729440T patent/ATE293169T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1349944A2 (en) | 2003-10-08 |
| AU2002219345B2 (en) | 2006-03-16 |
| WO2002055098A3 (en) | 2002-11-21 |
| DE60203692D1 (de) | 2005-05-19 |
| GB0100551D0 (en) | 2001-02-21 |
| JP4201253B2 (ja) | 2008-12-24 |
| US6942853B2 (en) | 2005-09-13 |
| ATE293169T1 (de) | 2005-04-15 |
| JP2004520031A (ja) | 2004-07-08 |
| ES2240740T3 (es) | 2005-10-16 |
| US20020151478A1 (en) | 2002-10-17 |
| DE60203692T2 (de) | 2006-03-02 |
| EP1349944B1 (en) | 2005-04-13 |
| WO2002055098A2 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE293169T1 (de) | Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen | |
| WO2002008251A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| ATE500323T1 (de) | Subtilisin-variante | |
| MXPA03000626A (es) | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. | |
| WO2002008256A3 (en) | Peptides as ns3-serine protease inhibitors of hepatitis c virus | |
| EA200901129A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| AR008727A1 (es) | COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO | |
| MXPA03000627A (es) | Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c. | |
| DK1337629T3 (da) | Dipeptidylpeptidaser | |
| MY120693A (en) | Human bikunin | |
| WO2006090385A3 (en) | Protease inhibitors and method of screening thereof | |
| DK1025237T3 (da) | Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder | |
| UA91820C2 (ru) | Терапевтическое применение вариантов хемокинов | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
| DE69941433D1 (de) | Von protease typ ii spaltbares peptid | |
| BR0312889A (pt) | Polipeptìdeo t20 peguilado | |
| FR2828405B1 (fr) | Vaccin anti-coronavirus | |
| DE60236330D1 (de) | Biologisch aktive Peptide | |
| WO2002008257A3 (en) | Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof | |
| WO2002034922A3 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof | |
| WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
| ATE503834T1 (de) | Bibliotheken rekombinanter chimärischer proteine | |
| DK1778271T3 (da) | Peptid til behandling af herpesvirusinfektioner | |
| WO2004053117A3 (en) | Serine protease |